Consensus statement of the european heart rhythm association: Updated recommendations for driving by patients with implantable cardioverter defibrillators

Europace

Volumn 11, Issue 8, 2009, Pages 1097-1107

  Vijgen, Johan ^a   Botto, Gianluca ^b   Camm, John ^c   Hoijer, Carl Johan ^d   Jung, Werner ^e   Le Heuzey, Jean Yves ^f   Lubinski, Andrzej ^g   Norekvål, Tone M ^h   Santomauro, Maurizio ⁱ   Schalij, Martin ^j   Schmid, Jean Paul ^k   Vardas, Panos ^l  

^a VIRGA JESSE HOSPITAL   (Belgium)

^b SANT ANNA HOSPITAL   (Italy)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e Academic Hospital Villingen   (Germany)

^f HCombining ogonekôpital Européen Georges Pompidou ^*  (France)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF BERN   (Switzerland)

^l UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAR DRIVING; CONFERENCE PAPER; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; MEDICAL SOCIETY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RISK ASSESSMENT; SECONDARY PREVENTION; SOCIAL PSYCHOLOGY;

ACCIDENT PREVENTION; ACCIDENTS, TRAFFIC; AUTOMOBILE DRIVING; DEFIBRILLATORS, IMPLANTABLE; DISABILITY EVALUATION; EUROPE; LICENSURE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 68649085404     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup112     Document Type: Conference Paper

References (105)

1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal sustained ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
2. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS et al. for the CIDS Investigators. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-1302.
3. Kuck KH, Cappato R, Siebels J, Rüppel R. for the CASH Investigators. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-54.
4. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al. Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med 1996;335:1933-40.
5. Bigger JT Jr, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implantable cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997;337:1569-75.
6. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G, for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-90.
7. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
8. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP et al. Defibril-lators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350;2151-8.
9. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amio-darone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
10. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, DeMarco T et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
11. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R et al. on behalf of the DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481-8.
12. Hammill SC, Kremers MS, Stevenson LW, Kadish AH, Heidenreich PA, Lindsay BD et al. National ICD Registry Annual Report 2007: review of the Registry's Second Year, data collected, and plans to add lead and pediatric ICD procedures. Heart Rhythm 2008;5:1359-63.
13. Ector H, Vardas P. Current use of pacemakers, implantable cardioverter defibrillators, and resynchronization devices: data from the registry of the European Heart Rhythm Association. Eur Heart J 2007;9 (Suppl. I):I44-9.
14. Proclemer A, Ghidina M, Gregori D, Facchin D, Rebellato L, Fioretti P et al. Impact of the main implantable cardioverter-defibrillator trials in clinical practice: data from the Italian ICD Registry for the years 2005-07. Europace 2009;11: 465-75.
15. Peinado R, Torrecilla EG, Ormaetxe J, Alvarez M. Spanish implantable cardioverter-defibrillator registry. Fourth official report of the Spanish society of cardiology working group on implantable cardioverter-defibrillators. Rev Esp Cardiol 2008;61:1191-203.
16. Anderson MH, Camm AJ. Legal and ethical aspects of driving and working in patients with an implantable cardioverter defibrillator. Am Heart J 1994;127: 1185-93.
17. Baker SP, Spitz WU. An evaluation of the hazard created by natural death at the wheel. N Engl J Med 1970;283:405-9.
18. Berger JT, Rosner F, Kark P, Bennett AJ. Reporting by physicians of impaired drivers and potentially impaired drivers. The Committee on Bioethical Issues of the Medical Society of the State of New York. J Gen Intern Med 2002;15: 667-72.
19. Binns H, Camm AJ. Driving and arrhythmias. BMJ 2000;324:927-8.
20. Grubb B. Driving and implantable cardioverter-defibrillator; a clearer view. J Am Coll Cardiol 2007;50:2241-2.
21. Bleakley JF, Akiyama T. Driving and arrhythmias: implications of new data. Card Electrophysiol Rev 2003;7:77-9.
22. Blitzer ML, Saliba BC, Ghantous AE, Marieb MA, Schoenfeld MH. Causes of impaired consciousness while driving a motorized vehicle. Am J Cardiol 2003; 91:1373-4.
23. Christian MS. Incidence and implications of natural deaths of road users. BMJ 1988;297:1021-4.
24. Finch NJ, Leman RB, Kratz JM, Gillette PC. Driving safety among patients with automatic implantable cardioverter defibrillators. JAMA 1993;270:1587-8.
25. Craney JM, Powers MT. Factors related to driving in persons with an implantable cardioverter defibrillator. Prog Cardiovasc Nurs 1995;10:12-7.
26. Jung W, Luderitz B. European policy on driving for patients with implantable car-dioverter defibrillators. Pacing Clin Electrophysiol 1996;19:981-4.
27. Jung W, Luderitz B. Quality of life and driving in recipients of the implantable cardioverter-defibrillator. Am J Cardiol 1996;78:51-6.
28. Smith TW. Driving after ventricular arrhythmias. N Engl J Med 2001;345:451-2.
29. Gimbel JR. When should patients be allowed to drive after ICD implantation? Cleve Clin J Med 2004;71:125-8.
30. Hartenbaum NP. What are the current guidelines on the use of implantable defi-brillators in transportation safety critical work? J Occup Environ Med 2005;47: 752-5.
31. Assessment of the cardiac patient for fitness to drive. Can J Cardiol 1992;8: 406-19.
32. Assessment of the cardiac patient for fitness to drive: 1996 update. Can J Cardiol 1996;12:1164-82.
33. Epstein AE, Miles WM, Benditt DG, Camm AJ, Darling EJ, Friedman PL et al. Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996;94:1147-66.
34. Jung W, Luderitz B. Driving and the implantable cardioverter defibrillator. Study Group on ICD and Driving. Lancet 1996;348:687-8.
35. Jung W, Anderson M, Camm AJ, Jordaens L, Petch MC, Rosenqvist M et al. Recommendations for driving of patients with implantable cardioverter defibrilla-tors. Study Group on 'ICD and Driving' of the Working Groups on Cardiac Pacing and Arrhythmias of the European Society of Cardiology. Eur Heart J 1997;18:1210-19.
36. Petch MC. Driving and heart disease. Eur Heart J 1998;19:1165-77.
37. The Cardiac Society for Australia and New Zealand. Cardiovascular disease and driving. Guidelines approved by the Council of the Cardiac Society of Australia and New Zealand on 29 November 2002.
38. Simpson C. CCS Consensus Conference 2003: assessment of the cardiac patient for fitness to drive and fly - executive summary. Can J Cardiol 2007;20:1313-23.
39. Epstein AE, Baessler CA, Curtis AB, Estes NA III, Gersh BJ, Grubb B et al. Addendum to 'Personal and Public Safety Issues Related to Arrhythmias That May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/ Scientific Statement From the American Heart Association and the North American Society of Pacing and Electrophysiology'. Public Safety Issues in Patients with Implantable Defibrillators. A Scientific Statement from the American Heart Association and the Heart Rhythm Society. Circulation 2007;115:1170-76.
40. http://www.snof.org/vue/permis-conduire.pdf
41. http://www.dvla.gov.uk/media/pdf/medical/aagv1.pdf
42. http://www.bivv.be/dispatch.wcs?uri=718209069&action= viewStream&language=nl
43. http://www.cbr.nl/brochure/2000%20Rijgeschiktheid%20bij%20ICD.pdf
44. Sears SF Jr, Todaro JF, Lewis TS, Sotile W, Conti JB. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol 1999;22:481-9.
45. Finch NJ, Leman RB, Kratz JM, Gillette PC. Driving safety among patients with automatic implantable cardioverter defibrillators. JAMA 1993;270:1587-8.
46. Dunbar SB. Psychosocial issues of patients with implantable cardioverter defibrillators. Am J Crit Care 2005;14:294-303.
47. Carroll DL, Hamilton GA. Long-term effects of implanted cardioverter-defibrillators on health status, quality of life, and psychological state. Am J Crit Care 2008;17:222-30.
48. Bostwick JM, Sola CL. An updated review of implantable cardioverter/defibrillators, induced anxiety, and quality of life. Psych Clinics North America 2007;30: 677-88.
49. Shea JB. Quality of life issues in patients with implantable cardioverter defibrilla-tors: driving, occupation, and recreation. AACN Clinical Issues 2004;15:478-89.
50. James J, Albarran JW, Tagney J. The experiences of ICD patients and their partners with regards to adjusting to an imposed driving ban: a qualitative study. Coronary Health Care 2001;5:80-88.
51. Eckert M, Jones T. How does an implantable cardioverter defibrillator (ICD) affect the lives of patients and their families? Intern J Nursing Practice 2002;8: 152-7.
52. Fridlund B, Lindgren EC, Ivarsson A, Jinhage BM, Bolse K, Flemme I et al. Patients with implantable cardioverter-defibrillators and their conceptions of the life situation: a qualitative analysis. J Clin Nursing 2000;9:37-45.
53. Craney JM, Powers MT. Factors related to driving in persons with an implantable cardioverter defibrillator. Progr Cardiovasc Nursing 1995;10:12-7.
54. Curtis AB, Conti JB, Tucker KJ, Kubilis PS, Reilly RE, Woodard DA. Motor vehicle accidents in patients with an implantable cardioverter-defibrillator. J Am Coll Card 1995;26:180-4.
55. Kelly R, Warke T, Steele I et al. Medical restrictions to driving: the awareness of patients and doctors. Postgrad Med J 1999;75:537-9.
56. Conti JB, Woodard DA, Tucker KJ, Bryant B, King LC, Curtis AB. Modification of patient driving behavior after implantation of a cardioverter defibrillator. Pacing Clin Electrophysiol 1997;20:2200-4.
57. Trappe HJ, Wenzlaff P, Grellman G. Should patients with implantable cardioverter-defibrillators be allowed to drive? Observations in 291 patients from a single center over an 11-year period. J Interv Card Electrophysiol 1998;2: 193-201.
58. Akiyama T, Powell JL, Mitchell LB, Ehlert FA, Baessler C. Resumption of driving after life-threatening ventricular tachyarrhythmia. New Engl J Med 2001;345: 391-7.
59. Maas R, Ventura R, Kretzschmar C, Aydin A, Schuchert A. Syncope, driving recommendations, and clinical reality: survey of patients. BMJ 2003;326:21.
60. Albert CM, Rosenthal L, Calkins H, Steinberg JS, Ruskin JN, Wang P et al. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study. J Am Coll Card 2007;50:2233-40.
61. Hickey K. Baseline factors predicting early resumption of driving after life-threatening arrhythmias in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. Am Heart J 2001;142:99-104.
62. Ostrom M, Eriksson A. Natural death while driving. J Forensic Sci 1987;32: 988-98.
63. Hossack DW. Death at the wheel. A consideration of cardiovascular disease as a contributory factor to road accidents. Med J Aust 1974;I:164-6.
64. Parsons M. Fits and other causes of loss of consciousness while driving. Q J Med 1986;58:295-303.
65. Antecol DH, Roberts WC. Sudden death behind the wheel from natural disease in drivers of four wheeled motor vehicles. Am J Cardiol 1990;66:1329-35.
66. Ontario Ministry of Transportation. Ontario Road Safety Annual Report. Toronto: Ontario Ministry of Transportation, 1987.
67. Fuel consumption survey annual report: October 1981 to September 1982 and October 1982 to September 1983 [Catalogue 53-226]. Ottawa: Statistics Canada, 1987.
68. Freedberg NA, Hill JN, Fogel RI, Prystowsky EN. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group. J Am Coll Card 2001;37:1910-15.
69. Levine JH, Mellits ED, Baumgardner RA, Veltri EP, Mower M, Grunwald L et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991;84:558-66.
70. Grimm W, Flores BF, Marchlinski FE. Symptoms and electrocardiographically documented rhythm preceding spontaneous shocks in patients with implantable cardioverter-defibrillator. Am J Cardiol 1993;71:1415-18.
71. Curtis JJ, Walls JT, Boley TM, Stephenson HE, Schmaltz RA, Nawarawong W et al. Time to first pulse after automatic implantable cardioverter defibrillator implantation. Ann Thorac Surg 1992;53:984-7.
72. Bansch D, Brunn J, Castrucci M, Weber M, Gietzen F, Borggrefe M et al. Syncope in patients with an implantable cardioverter-defibrillator: incidence, prediction and implications for driving restrictions. J Am Coll Cardiol 1998;31:608-15.
73. Tchou P, Axtell K, Anderson AJ, Keim S, Sra J, Troup P. When is it safe not to replace an implantable cardioverter defibrillator generator? Pacing Clin Electrophysiol 1991;14:1875-80.
74. Fogoros RN, Elson JJ, Bonnet CA. Actuarial incidence and pattern of occurrence of shocks following implantation of the automatic implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1989;12:1465-73.
75. Lubinski A, Bissinger A, Truszcz-Gluza M, Filipecki A, Kargul W, Zaja?c T et al. Potentially syncopal arrhythmias in ICD secondary prevention patients. Europace 2008;10 (Supp. 1):233 L6 (abstract).
76. Kou WH, Calkins H, Lewis R, Bolling SF, Kirsch MM, Langberg JJ et al. Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks. Ann Int Med 1991;115:942-5.
77. Freedberg NA, Hill JN, Fogel RI, Prystowsky EN. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group. J Am Coll Cardiol 2001;37:1910- 15.
78. Lerecouvreux M, Ait SM, Paziaud O, Perrier E, Carlioz R, Lavergne T et al. Automobile driving and implantable defibrillators. Arch Mal Coeur Vaiss 2005;98: 288-93.
79. Abello M, Merino JL, Peinado R, Gnoatto M, Arias MA, Gonzalez-Vasserot M et al. Syncope following cardioverter defibrillator implantation in patients with spontaneous syncopal monomorphic ventricular tachycardia. Eur Heart J 2006; 27:89-95.
80. Conti JB, Woodard DA, Tucker KJ, Bryant B, King LC, Curtis AB. Modification of patient driving behavior after implantation of a cardioverter defibrillator Pacing Clin Electrophysiol 1997;20:2200-4.
81. Curtis AB, Conti JB, Tucker KJ, Kubilis PS, Reilly RE, Woodard DA. Motor vehicle accidents in patients with an implantable cardioverter-defibrillator. J Am Coll Cardiol 1995;26:180-84.
82. Larsen GC, Stupey MR, Walance CG, Griffith KK, Cutler JE, Kron J et al. Recurrent cardiac events in survivors of ventricular fibrillation or tachycardia. Implications for driving restrictions. JAMA 1994;271:1335-9.
83. Alsheikh-Ali AA, Homer M, Maddukuri PV, Kalsmith B, Estes NA III, Link MS. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol 2008;19:784-9.
84. Raviele A, Gasparini G, for the Italian Endotak Investigator Group. Italian multi-center clinical experience with endocardial defibrillation: acute and long-term results in 307 patients. Pacing Clin Electrophysiol 1995;18:599-608.
85. Gold M, Peters R, Johnson J, Shorofsky S, for the World-wide Jewel Investigators. Complications associated with pectoral implantation of cardioverter defi-brillators. Pacing Clin Electrophysiol 1997;20:208-11.
86. Fahy G, Kleman J, Wilkoff B, Morant V, Pinski S. Low incidence of lead related complications associated with nonthoracotomy implantable cardioverter defi-brillator systems. Pacing Clin Electrophysiol 1995;18:172-8.
87. Danik S, Mansour M, Heist E, Ellinor P, Milan D, Singh J et al. Timing of delayed perforation with the St. Jude Riata lead: a single-center experience and a review of the literature. Heart Rhythm 2008;5:1667-72.
88. Ebstein AE, Baker JH, Beau SL, Deering TF, Greenberg SM, Goldman DS. Performance of the St. Jude Medical Riata Leads. Heart Rhythm 2009;6: 204-9.
89. Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices. Europace 2008;10:707-25.
90. Moss A, Greenberg H, Case R, Zareba W, Hall W, Brown M et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760-65.
91. Sesselberg H, Moss A, McNitt S, Zareba W, Daubert J, Andrews M, for the MADIT-II Research Group. Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: A MADIT-II substudy. Heart Rhythm 2007;4:1395-402.
92. Poole J, Johnson G, Hellkamp A, Anderson J, Callans D, Raitt M et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-17.
93. Singh J, Hall W, McNitt S, Wang H, Daubert J, Zareba W et al. and the MADIT-II investigators. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation. J Am Coll Cardiol 2005;46:1712-20.
94. Daubert J, Zareba W, Cannom D, McNitt S, Rosero S, Wang P et al. for the MADIT-II investigators. Inappropriate implantable cardioverter- defibrillator shocks in MADIT II. Frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51:1357-65.
95. Klein RC, Raitt MH, Wilkoff BL et al. Analysis of implantable cardioverter defi-brillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Cardiovasc Electrophysiol 2003;14:940-48.
96. Alter P, Waldhans S, Plachta E et al. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol 2005; 28:926-32.
97. Sweeney MO, Wathen MS, Volosin K et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005;111:2898-905.
98. Pacifico A, Hohnloser SH, Williams JH et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999;340:1855-62.
99. Connolly SJ, Dorian P, Roberts RS et al. Optimal pharmacological therapy in car-dioverter defibrillator patients I. Comparison of betablockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006;295:165-71.
100. Lee CH, Nam GB, Park HG, Kim HY, Park KM, Kim J et al. Effects of anti-arrhythmic drugs on inappropriate shocks in patients with implantable cardio-verter defibrillators. Circ J 2008;72:102-5.
101. Tzeis S, Andrikopoulos G, Kolb C, Vardas P. Tools and strategies for the reduction of inappropriate implantable cardioverter defibrillator shocks. Europace 2008;10:1256-65.
102. Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gérard F et al. Outcome after implantation of a Cardioverter-defibrillator in patients with Brugada syndrome. Circulation 2006;114:2317-24.
103. Vanhees L, Kornaat M, Defoor J, Aufdemkampe G, Schepers D, Stevens A et al. Effect of exercise training in patients with an implantable cardioverter defibrilla-tor. Eur Heart J 2004;25:1120-26.
104. Davids JS, McPherson CA, Earley C, Batsford WP, Lampert R. Benefits of cardiac rehabilitation in patients with implantable cardioverter-defibrillators: a patient survey. Arch Phys Med Rehabil 2005;86:1924-8.
105. Fitchet A, Doherty PJ, Bundy C, Bell W, Fitzpatrick AP, Garratt CJ et al. Comprehensive cardiac rehabilitation programme for implantable cardioverter-defibrillator patients: a randomised controlled trial. Heart 2003;89:155-60.